US SB1906 | 2015-2016 | 114th Congress
Status
Spectrum: Bipartisan Bill
Status: Introduced on July 30 2015 - 25% progression, died in committee
Action: 2015-07-30 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on July 30 2015 - 25% progression, died in committee
Action: 2015-07-30 - Read twice and referred to the Committee on Finance.
Pending: Senate Finance Committee
Text: Latest bill text (Introduced) [PDF]
Summary
Orphan Drug Fairness Act This bill amends the Patient Protection and Affordable Care Act (PPACA) to exclude sales of any drug or biological product approved by the Food and Drug Administration solely for rare diseases or conditions (orphan drug) from the calculation of the annual fee on manufacturers or importers with branded prescription drug sales exceeding $5 million. This Act is effective as if included in PPACA.
Title
Orphan Drug Fairness Act
Sponsors
| Sen. Robert Menendez [D-NJ] | Sen. Mike Crapo [R-ID] |
History
| Date | Chamber | Action |
|---|---|---|
| 2015-07-30 | Senate | Read twice and referred to the Committee on Finance. |
Same As/Similar To
HB3618 (Same As) 2015-10-02 - Referred to the Subcommittee on Health.
Subjects
Drug safety, medical device, and laboratory regulation
Drug therapy
Health
Income tax credits
Prescription drugs
User charges and fees
Drug therapy
Health
Income tax credits
Prescription drugs
User charges and fees
US Congress State Sources
| Type | Source |
|---|---|
| Summary | https://www.congress.gov/bill/114th-congress/senate-bill/1906/all-info |
| Text | https://www.congress.gov/114/bills/s1906/BILLS-114s1906is.pdf |
